Biodexa Pharmaceuticals Plc ADR (BDRX) Stock Price, Quote & News

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 29 2048 0180

Website: www.biodexapharma.com

Address:

1 Caspian Point, Caspian Way, Cardiff, United Kingdom

UptrendVale Jun. 9 at 6:07 PM

$HITI $EOSE $BDRX $QNRX Been on ZNB now

1 · Reply

Love_To_Learn Jun. 9 at 12:22 PM

$BDRX B NICE *

1 · Reply

Love_To_Learn Jun. 9 at 12:22 PM

$BDRX BROUGHT U KIDS TO PLAY WITH BEUD CHAI

0 · Reply

zzzzzzzzzzzxxx Jun. 5 at 12:36 PM

$BDRX one to short

0 · Reply

Technical_threat Jun. 3 at 3:44 PM

$BDRX one to watch

0 · Reply

okjasa Jun. 3 at 3:19 AM

$BDRX it doesn’t have the volume yet.

0 · Reply

The_Gambl3r Jun. 2 at 11:57 PM

$BTC.X $NUWE $BDRX

1 · Reply

Kesiya Jun. 2 at 10:22 AM

$SBFM /A Buy morex2 Float:2.13M Zero Borrow Fee 446.46% PT 5-10+ /Watchlist $ATPC $AVGO $BDRX $BLSG

1 · Reply

Linda1155 Jun. 2 at 1:05 AM

$BDRX on my watchingslist

0 · Reply

M105 Jun. 1 at 1:42 AM

$BDRX $IBM $NTCL $OLOX $SCNI it’s 309%+ and counting now, that’s why the dumb bear here is trying to make people believe his lies 😂😂😂😂 OLOX will bankrupt a lot of bears today 😂😂😂😂

0 · Reply

Biodexa issues letter to Shareholders

2026-04-02T23:50:17.000Z - 2 months ago

Biodexa Pharmaceuticals PLC-ADR trading halted, news pending

2026-04-02T13:12:12.000Z - 2 months ago

Biodexa Pharmaceuticals announces MTX240 manufacturing pact with Syngene

Apr 2, 2026, 8:30 AM EDT - 2 months ago

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

2026-03-31T12:47:27.000Z - 2 months ago

Biodexa, Tanner Pharma launch global early access program for FAP patients

Mar 27, 2026, 5:00 PM EDT - 2 months ago

Preliminary Results for the Year Ended 31 December 2025

2026-03-23T14:45:08.000Z - 2 months ago

Biodexa Pharmaceuticals management to meet with Maxim

Mar 23, 2026, 8:30 AM EDT - 2 months ago

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

2026-03-18T21:10:28.000Z - 2 months ago

Biodexa Pharmaceuticals announces one-for-five reverse ADR split

Mar 18, 2026, 5:00 PM EDT - 2 months ago

ADR Ratio Change

2026-03-09T12:40:09.000Z - 3 months ago

Biodexa Pharmaceuticals supports Life’s a Polyp Foundation

Mar 9, 2026, 8:30 AM EDT - 3 months ago

Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

Feb 19, 2026, 7:30 AM EST - 3 months ago

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

2026-02-04T13:36:46.000Z - 4 months ago

Biodexa Pharmaceuticals announces exclusive license with Otsuka Pharmaceutical

Feb 4, 2026, 8:30 AM EST - 4 months ago

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

2026-01-05T13:41:08.000Z - 5 months ago

Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary

Jan 5, 2026, 8:30 AM EST - 5 months ago

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

2025-12-18T13:35:26.000Z - 6 months ago

Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering

Dec 18, 2025, 8:30 AM EST - 6 months ago

Biodexa Announces Pricing of $10 Million Public Offering

2025-12-08T14:41:04.000Z - 6 months ago

Biodexa Pharmaceuticals PLC-ADR trading resumes

2025-12-08T14:35:30.000Z - 6 months ago

Biodexa Pharmaceuticals PLC-ADR trading halted, volatility trading pause

2025-12-01T13:35:58.000Z - 6 months ago

Biodexa announces enrollment of first European patients in Phase 3 Serenta trial

Dec 1, 2025, 8:30 AM EST - 6 months ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

2025-11-24T13:45:58.000Z - 7 months ago

Biodexa Pharmaceuticals activates first European Site for Phase 3 Serenta trial

Nov 24, 2025, 8:30 AM EST - 7 months ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

2025-11-17T22:05:23.000Z - 7 months ago

Biodexa Pharmaceuticals files to sell 3.38M units

2025-11-03T13:35:20.000Z - 7 months ago

Biodexa announces approval of CTA by EMA of Phase 3 trial in FAP

Nov 3, 2025, 8:30 AM EST - 7 months ago

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Oct 6, 2025, 8:30 AM EDT - 8 months ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

2025-09-26T21:05:13.000Z - 9 months ago

Biodexa Pharmaceuticals files $100M mixed securities shelf

2025-09-12T12:35:32.000Z - 9 months ago

Biodexa Pharmaceuticals reports 1H EPS (GBP0.0002) vs. (GBP0.001) last year

Sep 12, 2025, 8:30 AM EDT - 9 months ago

Interim results for the six months ended June 30, 2025

Sep 8, 2025, 7:00 AM EDT - 9 months ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

2025-08-18T12:35:17.000Z - 10 months ago

Biodexa announces enrollment of first two patients in Phase 3 Serenta trial

Aug 18, 2025, 8:30 AM EDT - 10 months ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 31, 2025, 9:30 AM EDT - 11 months ago

ADR Ratio Change Effective

Jul 28, 2025, 7:00 AM EDT - 11 months ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 14, 2025, 8:30 AM EDT - 11 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 1 year ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 11, 2025, 4:30 PM EDT - 1 year ago

Result of General Meeting

Jun 4, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

May 30, 2025, 8:30 AM EDT - 1 year ago

Shareholder Update

May 22, 2025, 4:30 PM EDT - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 12, 2025, 8:30 AM EDT - 1 year ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Notice of General Meeting

Apr 11, 2025, 8:30 AM EDT - 1 year ago

Preliminary Results for the Year Ended 31 December 2024

Mar 19, 2025, 7:00 AM EDT - 1 year ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Feb 24, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 13, 2025, 8:30 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 12, 2025, 7:30 AM EST - 1 year ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 10, 2025, 8:30 AM EST - 1 year ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Jan 22, 2025, 8:30 AM EST - 1 year ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Nov 21, 2024, 7:35 AM EST - 1 year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 12, 2024, 8:48 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

UptrendVale Jun. 9 at 6:07 PM

$HITI $EOSE $BDRX $QNRX Been on ZNB now

1 · Reply

Love_To_Learn Jun. 9 at 12:22 PM

$BDRX B NICE *

1 · Reply

Love_To_Learn Jun. 9 at 12:22 PM

$BDRX BROUGHT U KIDS TO PLAY WITH BEUD CHAI

0 · Reply

zzzzzzzzzzzxxx Jun. 5 at 12:36 PM

$BDRX one to short

0 · Reply

Technical_threat Jun. 3 at 3:44 PM

$BDRX one to watch

0 · Reply

okjasa Jun. 3 at 3:19 AM

$BDRX it doesn’t have the volume yet.

0 · Reply

The_Gambl3r Jun. 2 at 11:57 PM

$BTC.X $NUWE $BDRX

1 · Reply

Kesiya Jun. 2 at 10:22 AM

$SBFM /A Buy morex2 Float:2.13M Zero Borrow Fee 446.46% PT 5-10+ /Watchlist $ATPC $AVGO $BDRX $BLSG

1 · Reply

Linda1155 Jun. 2 at 1:05 AM

$BDRX on my watchingslist

0 · Reply

M105 Jun. 1 at 1:42 AM

0 · Reply

Kesiya Jun. 1 at 1:38 AM

#6 $SCNI /A Fee 217.52% Availa 150000 Float:8.91M /Watchlist $NTCL $OLOX $BDRX $IBM

0 · Reply

zzzzzzzzzzzxxx May. 30 at 9:04 AM

$BDRX

0 · Reply

BillionaireMotion May. 29 at 6:34 PM

$LMT $BDRX $BJDX 00

0 · Reply

luckyluke17 May. 29 at 1:18 PM

$BDRX heating up again

0 · Reply

luckyluke17 May. 27 at 3:07 PM

$BDRX short report comes out tonight. Let's see how the 906K short volume day has an effect on the mere 17K shares short on the last report before that day

0 · Reply

topstockalerts May. 24 at 2:41 PM

After Hours Top Gainers $ARTL $BDRX $QTEX $TKLF $MDRR

0 · Reply

topstockalerts May. 23 at 1:26 PM

$BDRX bears got trapped

0 · Reply

topstockalerts May. 23 at 2:54 AM

After Hours Top Gainers $ARTL $BDRX $QTEX $TKLF $MDRR

0 · Reply

topstockalerts May. 23 at 12:17 AM

$BDRX okay this is getting interesting now 👀

0 · Reply

LF5 May. 22 at 8:18 PM

$BDRX Getting some positive movement in ah.

0 · Reply

BillionaireMotion May. 21 at 10:34 PM

You miss all the insane 400%+ squeezers ??! Put ticker EZRA on watch ! Starting to make a move now and breakout! Looks like shorts could get squeezed hard.. EZRA has 515k shares remaining to the public only . We saw a mini spike earlier.. Would not be shocked at all if it runs soon. Always try to buy early before the crowd does 🚀 💎 $QNRX $BJDX $BDRX $HITI weed one

0 · Reply

The_Gambl3r May. 20 at 6:06 PM

$BDRX

0 · Reply

Market Cap	6.51M
Revenue (ttm)	0.00
Net Income (ttm)	-8.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.01

Volume	15,900
Avg Vol	927,354
Day's Range	N/A - N/A
Shares Out	2.00M
Stochastic %K	3%
Beta	1.23
Analysts	Strong Buy
Price Target	$35.00